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Our previous studies suggest that peroxisome proliferator–
activated receptor-a (PPARa) plays a critical role in regulating
fatty acid b-oxidation in kidney tissue and this directly
correlated with preservation of kidney morphology and
function during acute kidney injury. To further study this,
we generated transgenic mice expressing PPARa in the
proximal tubule under the control of the promoter of KAP2
(kidney androgen-regulated protein 2). Segment-specific
upregulation of PPARa expression by testosterone treatment
of female transgenic mice improved kidney function during
cisplatin or ischemia–reperfusion-induced acute kidney
injury. Ischemia–reperfusion injury or treatment with
cisplatin in wild-type mice caused inhibition of fatty-acid
oxidation, reduction of mitochondrial genes of oxidative
phosphorylation, mitochondrial DNA, fatty-acid metabolism,
and the tricarboxylic acid cycle. Similar injury in testosterone-
treated transgenic mice resulted in amelioration of these
effects. Similarly, there were increases in the levels of
4-hydroxy-2-hexenal-derived lipid peroxidation products in
wild-type mice, which were also reduced in the transgenic
mice. Similarly, necrosis of the S3 segment was reduced in
the two injury models in transgenic mice compared to wild
type. Our results suggest proximal tubule PPARa activity
serves as a metabolic sensor. Its increased expression without
the use of an exogenous PPARa ligand in the transgenic
mice is sufficient to protect kidney function and morphology,
and to prevent abnormalities in lipid metabolism associated
with acute kidney injury.
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Peroxisome proliferator–activated receptors (PPARs) are
transcription factors belonging to the ligand-activated
nuclear hormone receptor superfamily.1 Through hetero-
dimerization with retinoid X receptor (RXR) and binding to
the PPAR response elements (PPREs) in the promoter of
target genes, PPARs have been shown to have critical roles in
regulating pleiotropic biological process, including lipid and
glucose metabolism, adipogenesis, immune response, and
cell growth and differentiation.2,3 There are three major sub-
types: PPARa, PPARb/d, and PPARg. PPARa is predomi-
nantly expressed in metabolically very active tissues, such as
liver, heart, renal proximal tubular cells (kidney), skeletal
muscle, and brown fat.4,5 Increased evidence suggests PPARa
has an important role in the regulation of energy home-
ostasis.6 PPARa activates fatty acid catabolism by induction
of target genes encoding fatty acid oxidation (FAO) enzymes
in the mitochondria and peroxisomes, as well as proteins
involved in cellular fatty acid import. In addition, PPARa not
only stimulates gluconeogenesis and ketone body synthesis
but also has a significant anti-inflammatory activity that
seems to have a protective role and suppress apoptosis.7
PPARa is a short-lived protein and is degraded by the
ubiquitin–proteasome system. Its transcriptional activity is
regulated by various factors at several levels. These include
the regulation of its expression and stability, the nature and
the level of endogenous or synthetic ligand, the co-activator
and co-repressor proteins, and post-translational modifica-
tions of PPARa and associated activator and repressor.
PPARa is highly expressed in the kidney, predominantly in
the proximal tubule and in medullary thick ascending limb of
Henle. Fatty acids constitute a major source of metabolic fuel
for energy production in kidney cortex tissue, and activation
of PPARa by various ligands can induce the expression of
genes involved in controlling renal fatty acid b-oxidation. In
previous studies, we have observed that the inhibition of
peroxisomal and mitochondrial FAO enzymes in kidney
tissue of mice undergoing ischemia/reperfusion (I/R)- and
cisplatin (CP)-induced acute kidney injury (AKI) results
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from reduced transcriptional activity of PPARa.8–14 Failure to
oxidize long-chain fatty acids and long-chain acylcarnitines
during AKI results in their accumulation and cellular toxicity,
which further contributes to proximal tubule cell death.8,9 We
also documented that the administration of fibrate, a known
PPARa ligand, before AKI (1) prevented the inhibition of
FAO and the accumulation of non-esterified fatty acids and
triglyceride in kidney tissue; and (2) fibrates ameliorated
apoptotic and necrotic proximal tubule cell death, resulting
in significant protection of renal function only in PPARa
wild-type mice, and not in PPARa-null mice.11–15 Altogether,
these observations would suggest a critical role for PPARa in
regulating fatty acid b-oxidation in kidney tissue that directly
correlates with the preservation of kidney morphology and
function during CP- and I/R-induced AKI. To further
investigate the physiological role of PPARa in kidney, and
to determine whether the upregulation of PPARa expression
alone without the use of a synthetic ligand is sufficient to
activate FAO in the kidney and to ameliorate renal function
from CP- or I/R-induced AKI, we generated transgenic (Tg)
mice that express mouse PPARa under the control of kidney
androgen-regulated protein 2 (KAP2) promoter, which is
androgen-responsive. This promoter has been used with
success to generate mice that show proximal tubule and
androgen-specific expression of human rennin.16 More
recently, KAP2 promoter was used to develop Tg mice that
express proximal tubule-specific Cre recombinase activity.17
In our KAP2-PPARa Tg mice reported here, renal PPARa
expression was detectable in proximal tubules of female Tg
mice and could be induced by testosterone treatment. In
comparison with wild-type mice, without synthetic ligand,
the upregulation of PPARa expression by testosterone
treatment in the KAP2-PPARa female Tg mice prevented
CP- and I/R-induced inhibition of FAO and protected kidney
function and morphology from CP- or I/R-induced AKI.
RESULTS
Generation and characterization of the KAP2-PPARa Tg mice
KAP2-PPARa Tg mice were generated to produce a tissue-
specific and androgen-inducible expression of mouse PPARa
in the proximal tubules of the kidney. Three founder Tg lines
were obtained and all transmitted the KAP2-PPARa Tg to
their progeny. Tg expression was evaluated in kidney, liver,
heart, and brain tissues. Of the three founder Tg lines (#560,
#561, and #562), all three lines were shown to express the
Tg in the kidney by reverse transcription-PCR (RT-PCR) and
real-time RT-PCR analysis. The highest level of KAP2-PPARa
Tg expression was observed with line 562, therefore the
studies presented in this study were performed in line 562.
However, analogous results were obtained with line 561.
As shown in Figure 1a, Tg FLAG-PPARa mRNA level
was detected only in the kidney of KAP2-PPARa Tg mice.
In addition, when KAP2-PPARa Tg mice were given testo-
sterone, the expression of FLAG-PPARa was increased only
in kidney but not in heart, liver, or brain tissue as shown in
Figure 1b. As PPARa is normally expressed in heart, liver, and
kidney tissue of wild-type mice, we then carried out real-time
RT-PCR analysis using total RNA isolated from kidney, heart,
and liver tissues of wild-type and Tg mice, and specific
oligonucleotides to measure total PPARa mRNA levels
(Tg þ endogenous). As shown in Figure 1c, PPARa (Tg þ
endogenous) was increased about 2.4-fold only in kidney
tissue of KAP2-PPARa Tg mice but not in the liver or heart
tissue. To assess the inducibility of the KAP2 promoter, Tg
female mice from line 562 were implanted with a testosterone
pellet. After 14 days, the mice were killed, and tissues were
collected for further analysis of the PPARa gene expression.
When testosterone was given to either wild-type or KAP2-
PPARa Tg mice, PPARa expression was increased only in
kidney but not in liver or heart tissue. These results shown in
Figure 1c further support the specificity of the expression of
KAP2-PPARa Tg mice in kidney tissue, as well as the
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Figure 1 |Tissue-specific induction of renal PPARa mRNA
in female KAP2-PPARa transgenic mice by testosterone.
(a) Tissue-specific expression of epitope (FLAG)-tagged
peroxisome proliferator-activated receptor-a (PPARa) (FPPARa).
Reverse transcriptase-PCR (RT-PCR) result of 5 mg total RNA from
transgenic (Tg) or wild-type (WT) female mice with specific
primers to FLAG and PPARa. (b) Induction of renal FPPARa mRNA
expression by testosterone. Total RNA was isolated from the
kidney, liver, heart, and brain in the absence or presence of
testosterone pretreatment. (c) Quantitative real-time PCR of
PPARa mRNA expression levels in wild-type and kidney androgen-
regulated protein 2 (KAP2)-PPARa Tg mice. Bars represent
mean±s.e. mRNA levels for at least four samples in each group
as determined by quantitative real-time RT-PCR. Data are
normalized against the housekeeping gene glyceraldehyde-3-
phosphate dehydrogenase (GAPDH).
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inducibility of PPARa gene in kidney tissue when testo-
sterone was given. The increased mRNA expression of PPARa
in kidney tissue of KAP2-PPARa Tg mice was also correlated
with the increased protein levels of PPARa in kidney tissue.
Our studies using anti-PPARa antibodies followed by
immunoprecipitation and western blot analysis of kidney
tissue obtained from KAP2-PPARa Tg mice showed that
testosterone induced a 3.5-fold increase in PPARa protein
levels (Figure 2).
Androgen-induced PPARa in the kidney protects kidney
function during CP- and ischemic-induced AKI in KAP2-PPARa
Tg mice
To determine the role of increased expression and activity
of PPARa protein in the kidney proximal tubule, kidney
function was monitored by measuring serum blood urea
nitrogen (BUN) and creatinine for 2 days after single intra-
peritoneal injection of saline or CP. Figure 3a and b presents
the changes in BUN and serum creatinine seen in KAP2-
PPARa Tg or wild-type mice treated with saline or CP in the
absence or presence of testosterone. Comparison of the renal
function between wild-type mice pretreated with or without
testosterone did not show differences in BUN and creatinine
after saline injection (BUN: 7.85 and 8.39 mM, respectively;
creatinine: 23.76 and 22 mM, respectively). Wild-type mice
developed significant AKI in both groups at day 2 after CP
injection (BUN: 100.35 and 94.59 mM, respectively; creatinine
233.2 and 205.04 mM, respectively). In contrast, KAP2-PPARa
Tg mice, pretreated with testosterone before CP administra-
tion, showed protection in renal function on day 2 (BUN:
10.36 mM, creatinine: 33.44 mM). However, KAP2-PPARa Tg
mice without testosterone pretreatment developed AKI at
day 2 (BUN: 94.15 mM, creatinine: 193.6 mM) after CP injec-
tion. These observations suggest that the protective effect on
renal function in KAP2-PPARa Tg mice was dependent
on testosterone-mediated increased expression of proximal
tubule PPARa.
To investigate whether testosterone-induced PPARa
expression had a similar effect in protecting kidney function
during acute ischemic renal failure, we used an I/R model
in both wild-type and KAP2-PPARa Tg mice. As shown
in Figure 3c and d, the serum BUN and creatinine levels were
much higher in wild-type mice (53.63 mM and 169.84mM,
respectively) that were subjected to I/R injury when
compared with KAP2-PPARa Tg mice (13.99 mM and
49.28 mM, respectively), which further supports our previous
observations of amelioration of renal function by increasing
the expression of proximal tubule PPARa before I/R injury.
Kaplan–Meier survival curves
We have assessed survival time using the model of 50 min of
ischemia followed by reperfusion injury. In this model, serum
BUN and creatinine were lower in our KAP2-PPARa Tg mice
at 24 h of reperfusion when compared with wild-type mice as
shown in Figure 3c and d. At 48 h of reperfusion, serum BUN
and serum creatinine were already improved in wild-type
mice when compared with sham-operated mice (results
not shown). We did observe wild-type and KAP2-PPARa Tg
mice for 5 days of reperfusion after 50 min of ischemia
and did not see an increase in mortality in wild-type mice
when compared with KAP2-PPARa Tg mice. In contrast, in
the model of CP-mediated acute renal failure, we did see a
significant improvement in survival rate in our KAP2-PPARa
Tg mice when compared with wild-type mice. These data are
shown in Figure 4. At 3 days after CP injection, the survival
rate in wild-type mice was 60% when compared with 100%
survival rate in KAP2-PPARa Tg mice. At day 4, survival rate
for wild-type mice was only 28.6% when compared with
100% in KAP2-PPARa Tg mice. At day 5, survival rate for
wild-type mice was 0% (all wild-type mice were dead at day 5
after CP injection), whereas the survival rate was reduced to
60% in KAP2-PPARa Tg mice that received the same dose of
CP than the wild-type mice (P¼ 0.00726). We subsequently
observed KAP2-PPARa Tg mice for 7 days after CP injection,
and the survival rate did not change and was still 60%. There
was no mortality in the sham-operated or saline-treated
control mice (data not shown). On the basis of these results,
we believe that the course of CP-mediated acute renal failure
in our hands was more severe than the injury seen in I/R
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Figure 2 | Testosterone-induced PPARa protein expression
in female KAP2-PPARa transgenic mice. (a) A representative
autoradiogram of one single experiment of western blot
analysis of immunoprecipitated peroxisome proliferator-activated
receptor-a (PPARa) from kidney androgen-regulated protein 2
(KAP2)-PPARa transgenic (Tg) mouse kidney tissue. Immuno-
precipitates (fractions F1, F2, F3) from mouse kidney tissues with
(þ Testosterone) or without testosterone ( Testosterone)
treatment. (b) Quantification of renal PPARa protein expression in
the absence or presence of testosterone was carried out using
kidney tissues of KAP2-PPARa Tg mice. This figure represents
a summary of three separate experiments. Bars represent
means±s.e. of three separate experiments.
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injury, and we were able to establish significant differences in
survival rate when comparing wild-type mice that received
testosterone and then CP with KAP2-PPARa Tg mice that
did also receive testosterone and then CP. On the basis of
these results, we conclude that the observed increased
survival rate in KAP2-PPARa Tg mice that received CP and
developed acute renal failure further supports a true protec-
tion against acute renal failure.
Immunolocalization of PPARa and morphological alterations
in kidney tissue
PPARa staining was primarily localized to the thick ascend-
ing limbs of loop of Henle and the early parts (S1 and S2
segments) of proximal tubules in untreated wild-type animals.
Furthermore, occasional positive staining with random nuclear
appearance could be seen in the S3 segment of proximal
tubules. PPARa staining was significantly decreased through-
out the kidney 2 days after CP administration in these wild-
type mice (Figure 5a and b). In contrast, very strong diffuse
staining pattern could be detected in the entire kidney cortex
including the S3 segments of proximal tubules in untreated
KAP2-PPARa Tg mice after testosterone induction (Figure 5c).
This positive staining remained unchanged in testosterone-
treated KAP2-PPARa Tg mice 2 days after CP treatment
(Figure 5d). Morphologic kidney damage was also markedly
reduced in testosterone-treated KAP2-PPARa Tg mice 2 days
after CP administration. Evaluation of the morphological
differences (Figure 5b) showed small necrotic foci; severe
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Figure 3 | Effects of cisplatin (Cisp) and ischemia/reperfusion (I/R) injury on renal function: Pretreatment with testosterone in
female kidney androgen-regulated protein 2-peroxisome proliferator-activated receptor-a (KAP2-PPARa) transgenic (Tg) mice
prevented Cisp- or I/R-induced acute kidney injury (AKI). Serum blood urea nitrogen (BUN) (a, c) and creatinine (b, d) levels were
measured at day 2 after Cisp injection (a, b) in the absence or presence of 14-day testosterone pellet pretreatment or 24 h after 50 min
ischemia operation (c, d) in the presence of 14-day testosterone pretreatment. Bars represent means±s.e. of at least four independent
experiments under each condition. *Po0.05 compared with control (wild-type (WT)þ saline without testosterone) or sham, wPo0.05
compared with TgþCisp without testosterone pretreatment in unpaired Student’s t-test.
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Figure 4 |Kaplan–Meier survival curve. Comparison of
the survival rate of wild-type (WT) and kidney androgen-regulated
protein 2-peroxisome proliferator-activated receptor-a
(KAP2-PPARa) transgenic mice after cisplatin (CP) administration
in the presence of testosterone pretreatment. Statistical
significance was assessed by the log-rank test.
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degeneration accompanied by the loss of brush border, tubular
dilatation, and cast formation in wild-type mice. The analyzed
parameters were significantly reduced in the KAP2-PPARa Tg
group and only mild degeneration and brush border loss could
be detected in some areas of the kidney (Figure 5d) in KAP2-
PPARa Tg mice treated with CP and testosterone. Similar
results were also observed in the I/R-induced AKI model. The
sham mouse kidneys in some instances exhibited very mild
pathological changes such as occasional loss of bush border
and presence of few inflammatory cells (Figure 6a). All wild-
type mice undergoing I/R injury had extensive tubular necrosis
at the cortico-medullary junction (S3 segment of proximal
tubules), loss off brush border, leukocyte infiltration, and
numerous casts throughout the kidney (Figure 6b). In
contrast, testosterone-induced PPARa Tg ischemic kidney
showed significantly improved morphology. They had only
mild loss of brush border and tubular dilatation, and only very
few necrotic tubules were found occasionally in some kidney
sections. There was only minimal leukocyte infiltrate and very
few casts (Figure 6c).
The semi-quantitative analysis of morphological damages
in CP-treated mice has shown statistically significant changes
in proximal tubule cell necrosis (Figure 7a), and tubular
degeneration when PPARa Tg mice were induced with
testosterone treatment. In the I/R model of AKI, as shown in
Figure 7b, there were statistically significant changes in
proximal tubule cell necrosis, cast formation, and tubular
degeneration when PPARa was induced with testosterone
treatment when compared with wild-type mice subjected to
I/R injury.
Inhibition of renal FAO by CP or I/R-induced AKI is prevented
in KAP2-PPARa Tg mice
To determine the mechanisms by which renal function was
ameliorated in KAP2-PPARa Tg mice treated with CP, we
examined the effects of CP and testosterone on the expression
of PPARa target genes involved in renal FAO in both KAP2-
PPARa Tg and wild-type mice. As shown in Figures 8 and 9,
the mRNA expression levels of medium-chain acyl-coenzyme
A dehydrogenase (MCAD), long-chain acyl coenzyme dehy-
drogenase (LCAD), very-long-chain acyl coenzyme dehydro-
genase (VLCAD), and liver carnitine palmytoyltransferase-1
(L-CPT1) showed no significant changes (only 1.1- to 1.3-
fold increase) in KAP2-PPARa Tg mice when compared with
levels in wild-type mice. For both wild-type and KAP2-
PPARa Tg mice, CP caused a significant decline (Po0.05) in
the mRNA expression of MCAD (85 and 76%, respectively),
LCAD (41 and 30%, respectively), VLCAD (68 and 61%,
respectively), and L-CPT1 (79 and 62%, respectively).
Pretreatment with testosterone prevented CP-induced in-
hibition of renal FAO expression in KAP2-PPARa Tg mice,
but this effect was not observed in the wild-type mice. These
results are similar to our previously published observations,
Figure 5 | Immunolocalization of PPARa in kidney tissue.
Immunolocalization of peroxisome proliferator-activated
receptor-a (PPARa) in the kidneys of untreated
saline control (a), cisplatin (CP)-treated wild-type (b), testosterone-
induced untreated (c), CP-treated PPARa transgenic mice
(d) 2 days after CP administration. Immunostaining of
kidney tissue using PPARa antibody in wild-type mice
showed only occasional positive staining in the S3 segment
(a) that was significantly reduced in the CP-treated mice
(b). Strong positive staining was detected after testosterone
implantation in kidney androgen-regulated protein 2 (KAP2)-
PPARa transgenic mice in the S3 segment of proximal tubules
(c), which remained unchanged after CP administration
(d). Asterisk: proximal tubules; arrowheads: thick ascending loop
of Henle; arrows: necrotic foci. Original magnification, 250.
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Figure 6 |Comparison of morphological damage in the
cortico-medullary junction from control and ischemic kidneys
24 h after reperfusion. Representative photographs of periodic
acid-Schiff (PAS)-stained sections of sham (a), testosterone-
pretreated wild-type ischemia/reperfusion (b), and testosterone-
induced peroxisome proliferator-activated receptor-a (PPARa)
transgenic ischemia/reperfusion (c) mouse kidneys. The sham
kidney shows normal kidney architecture (a), whereas extensive
necrosis, loss of brush border, cast formation, and inflammatory
cells can be seen in a typical wild-type ischemic kidney 24 h after
reperfusion (b). A typical testosterone-induced ischemic PPARa
transgenic kidney (c) appeared to be almost normal. Only some
loss of brush border, tubular dilatation, and single, partially
necrotic tubules could be seen occasionally. Asterisks: proximal
tubules; arrowheads: thick ascending loop of Henle; arrow:
necrotic foci, NT: necrotic tubule. Original magnification, 125.
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in which the use of PPARa ligands etomoxir and fibrates
resulted in the upregulation of renal FAO during I/R- and
CP-induced AKI. Therefore, again these observations further
support the cytoprotective role of PPARa on renal function
during AKI and further underscore the importance of
mitochondrial FAO on the preservation of structure and
function of the proximal tubule during AKI. As testosterone
prevented CP-induced reduction of MCAD mRNA levels in
the KAP2-PPARa Tg mice but not in the wild-type mice, we
next examined the effects of CP and testosterone on MCAD
enzyme activity. As shown in Figure 8b, CP on day 2 caused a
profound decline (Po0.05) in the enzyme activity of renal
MCAD in both wild-type and KAP2-PPARa Tg mice (61 and
59%, respectively). Pretreatment with testosterone prevented
CP-induced inhibition of renal MCAD activity in KAP2-
PPARa Tg mice. In contrast to the effects of testosterone on
KAP2-PPARa Tg mice, pretreatment with testosterone did
not affect CP-induced reduction of MCAD activity in wild-
type mice. Similar results were observed in I/R-induced AKI
model, as shown in Figures 8c, d and 9d. Pretreatment with
testosterone prevented I/R-induced inhibition of renal FAO
expression and MCAD activity in KAP2-PPARa Tg mice, but
not in the wild-type mice. These data indicate that the
protective effect of testosterone on mRNA levels and activity
of FAO enzyme MCAD were dependent on the activation of
KAP2 promoter and the induction of PPARa expression in
the proximal tubule of KAP2-PPARa Tg mice.
Mitochondrial genes affected by CP in untreated and
testosterone-treated KAP2-PPARa Tg mice
Microarray data analysis showed that CP treatment signifi-
cantly reduced the expression of 454 (84%) of mitochondria-
related genes with a false discovery rate ofp0.05 in PPARa Tg
mice. A noteworthy observation was downregulation of genes
associated with oxidative phosphorylation (complexes I–V),
mitochondrial DNA replication and repair, fatty acid meta-
bolism, and tricarboxylic acid (TCA) cycle (Table S1, data not
shown). Interestingly, however, pretreatment with testosterone
of PPARa Tg mice was protective against CP-mediated
inhibition of mitochondria-related gene expression to the
extent that the expression levels of the majority of mitochon-
drial genes inhibited by CP was almost restored to baseline
levels (Figure 10 and Table 1).
Volcano plot
To get a better insight into the effect of CP on expression levels
of mitochondria-related genes in the presence and absence of
testosterone in PPARa Tg animals, microarray data from
animals treated with CP and KAP2-PPARa Tg mice pre-
administered testosterone followed by exposure to CP were
presented in a volcano plot (Figure 10). Volcano plot is a
graphic presentation of relative fold changes against false
discovery rate for each gene evaluated. This allows a
simultaneous intuitive assessment of the extent of fold changes
and the significance associated with each gene in response to
both treatments. A majority of mitochondria-related genes
(84%) were downregulated by CP treatment. whereas pretreat-
ment with testosterone seemed to reverse CP-induced changes
in expression levels of these genes (Table S2, data not shown.
Tables S1 and S2 are not included in the main paper because of
their large number of pages; however, can be made available
upon request of the reviewers). As shown in Figure 10, there
was a significant statistical difference in mitochondrial gene
expression in kidney tissue of KAP2-PPARa Tg mice treated
with CP in the absence of testosterone (red open circles) and
kidney tissue of KAP2-PPARa Tg mice treated with testoster-
one (blue open circles), which further supports the protective
effect of testosterone by increasing the expression of mitochon-
drial genes that were downregulated by CP treatment, an effect
associated with amelioration of renal function.
Effect of increased proximal tubule PPARa on AKI-mediated
formation of lipid peroxidation products
Mouse kidney cortex tissue uses polyunsaturated fatty acids
as a source of energy production.18,19 Lipid peroxidation of
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Figure 7 |Morphological changes in PPARa Tg mice subjected
to I/R or Cisplatin-induced AKI. Morphological evaluation of
cisplatin (CP)-treated peroxisome proliferator-activated receptor-a
(PPARa) transgenic (Tg) mouse kidneys with or without induction of
the transgene with testosterone (testos) (a) or ischemia/reperfusion
(I/R)-induced acute kidney injury (AKI) (b). Bars represent
means±s.e. of kidney sections from at least five mice in each group.
*Po0.05 compared with control (Tgþ saline without testosterone)
or sham, wPo0.05 compared with TgþCP without testosterone
pretreatment or I/R-wild-type (WT) in unpaired Student’s t-test.
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polyunsaturated fatty acids leads to the formation of
cytotoxic lipid-aldehyde species, which includes 4-hydroxy-
2-nonenal (4-HNE) and 4-hydroxy-2-hexenal (4-HHE),
products derived from lipid peroxidation of n-6 and n-3
fatty acids, respectively.20 Previous studies have documented
an increased formation of HHE in kidney tissue after I/R
injury.21 In this study, we have used a primary monoclonal
antibody against HHE to determine whether lipid peroxida-
tion product 4-HHE is affected by increased expression of
proximal tubule PPARa in our KAP2-PPARa Tg mice.
Immunohistochemical staining using antibody against HHE-
modified proteins showed that CP administration led to
increased staining of cytoplasmic HHE in renal proximal
tubular cells from Tg mice without testosterone implanta-
tion. HHE staining was significantly reduced or almost
absent in the kidney tissue of KAP2-PPARa Tg mice treated
with testosterone and then with CP (Figure 11). Western blot
analysis using the kidney tissue of CP- or I/R-treated mice
also showed increased formation of HHE-modified proteins
as shown in Figure 12. CP and I/R injury led to 2.9- and 3.9-
fold increase in the amount of renal HHE-modified protein,
respectively. Pretreatment with testosterone reduced CP- and
I/R injury-induced renal HHE-modified protein in KAP2-
PPARa Tg mice when PPARa was induced.
DISCUSSION
In our previous studies using fibrates and targeted disruption
of the mouse PPARa gene, we showed that fibrate-induced
amelioration of renal function during AKI was the result of
increased transcriptional activity of PPARa gene.8–15,22–24
Other investigators have confirmed these observations
regarding the renal protective effect of using fibrates in
various animal models of acute renal failure.15,18 In this
study, we have developed and characterized Tg mice
expressing PPARa by driving the expression of PPARa with
a proximal tubule-specific and androgen-regulated promo-
ter,16,17,25,26 in order to directly examine the cytoprotective
effect of PPARa in kidney tissue. In these female KAP2-
PPARa Tg mice, testosterone induced the expression of
PPARa in proximal tubule. We find that increased proximal
tubule PPARa has a significant effect on ameliorating the
renal function in the models of I/R- and CP-mediated AKI. In
addition, survival rate at day 5 after CP injection is signi-
ficantly increased in KAP2 PPARa Tg mice that received CP
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Figure 8 |Changes in MCAD mRNA levels and enzyme activity after Cisp- and I/R-induced AKI. Pretreatment with testosterone
prevented cisplatin (Cisp)- or ischemia/reperfusion (I/R)-induced inhibition of renal medium-chain acyl-coenzyme A dehydrogenase (MCAD)
mRNA expression (a, c) and enzyme activity of MCAD (b, d) in KAP2-PPARa transgenic (Tg) mice. Wild-type (WT) or kidney androgen-
regulated protein 2-peroxisome proliferator-activated receptor-a (KAP2-PPARa) Tg mice female mice were administered Cisp in the absence
or presence of 14-day testosterone pretreatment or underwent 50-min ischemia operation in the presence of 14-day testosterone
pretreatment. (a and c) Levels of renal MCAD mRNA were determined by quantitative real-time reverse transcriptase-PCR (RT-PCR). (b and d)
MCAD enzyme activity was determined as described in Materials and Methods. Bars represent mean±s.e. mRNA levels or MCAD enzyme
activity for at least four mice in each group. *Po0.05 compared with control (WTþ saline without testosterone) or sham, wPo0.05
compared with TgþCisp without testosterone pretreatment in unpaired Student’s t-test.
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when compared with wild-type mice. Of importance, such an
effect did not require the administration of an exogenous
PPARa ligand-like fibrate.
The findings in our KAP2 PPARa Tg mice are in contrast
with the findings reported in a previously described Tg
mouse model (MHC-PPARa), in which PPARa was
overexpressed (80- to 135-fold increase) in the postnatal
heart driven by the a-myosin heavy-chain promoter. In
MHC-PPARa Tg mice, FAO rates were increased and glucose
uptake and metabolism were decreased, leading to a
metabolic phenotype that had remarkable similarities to
diabetic heart.27,28 In addition, older MHC-PPARa mice also
exhibited features of diabetic cardiomyopathy, including the
activation of gene markers of pathological hypertrophic
growth and alterations in systolic and diastolic function.27
Unlike that study, the inducible and reversible expression of
PPARa in kidney tissue controlled by androgen avoids the
potential disadvantages caused by the constitutive over-
expression of PPARa in heart tissue. Therefore, we believe
that when compared with the MHC-PPARa Tg mice, the
absence of phenotype in the KAP2-PPARa Tg mice could
relate to the magnitude of the increased expression of PPARa
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Figure 9 | Effects of cisplatin (Cisp) and ischemia/reperfusion (I/R) injury on mRNA levels of fatty acid oxidation (FAO) genes.
Pretreatment with testosterone prevented (a–c) Cisp- or (d) I/R-induced inhibition of the mRNA levels of renal FAO-related genes LCAD,
VLCAD, and L-CPT1 in KAP2-PPARa transgenic (Tg) mice. Wild-type (WT) or KAP2-PPARa Tg female mice were administered Cisp in the
absence or presence of 14-day testosterone pretreatment or underwent 50-min ischemia operation in the presence of 14-day testosterone
pretreatment. Levels of renal long-chain acyl coenzyme dehydrogenase (LCAD), very-long-chain acyl coenzyme dehydrogenase (VLCAD),
and liver carnitine palmytoyltransferase-1 (L-CPT1) were determined by quantitative real-time RT-PCR. Bars represent mean±s.e. mRNA
levels for at least four mice in each group. *Po0.05 compared with control (WTþ saline without testosterone) or sham, wPo0.05 compared
with TGþCisp without testosterone pretreatment or I/R-WT in unpaired Student’s t-test.
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Figure 10 | (Volcano plot) Pretreatment with testosterone
modulated the expression level of mitochondria-related
genes that were downregulated by cisplatin (CP) in kidney
androgen-regulated protein 2-peroxisome proliferator-
activated receptor-a (KAP2-PPARa) transgenic mice. Red open
circles indicate the effect of CP in PPARa transgenic mice in the
absence of testosterone and blue open circles indicate the effect of
CP in KAP2-PPARa transgenic mice pretreated with testosterone.
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in kidney tissue, which corresponded only to a moderate
(3.5-fold) overexpression of PPARa in kidney tissue when
KAP2-PPARa Tg mice were treated with testosterone.
It is important to point out in our study that using the
two models of CP- and I/R-induced AKI, we find at least four
independent but interrelated mechanisms that could account
for the cytoprotective effects of increasing the expression
of proximal tubule PPARa during AKI. We observed that
CP- and I/R-mediated reduced expression of mitochondrial
FAO genes, seen in wild-type females or female Tg mice not
treated with testosterone pellet, was prevented when the
expression of proximal tubule PPARa was increased with the
use of testosterone. Testosterone by itself did not have any
protective effect on renal function in wild-type female mice.
Therefore, our studies suggest that increased FAO in the
proximal tubule by increased expression of PPARa represents
an important mechanism by which renal function can be
preserved in our KAP2-PPARa Tg mice. A second mechan-
ism that could explain why KAP2-PPARa Tg mice were
protected during CP-mediated AKI was the observed
increased expression of mitochondrial genes associated with
oxidative phosphorylation (complexes I–V), mitochondrial
DNA replication and repair, fatty acid metabolism, and TCA
cycle as shown in Table 1. Those findings corroborate
previous observations in fibrate-treated mice showing that
PPARa directly modulates mitochondrial biogenesis and
function9,29,30 (Figure 10 and Table 1).
A third mechanism by which increased expression of
kidney tissue PPARa ameliorated AKI was a reduced
formation of lipid peroxidation products. Lipid peroxidation
products include hydroperoxides, aldehydes such as 4-HHE
and 4-HNE, and polymeric materials. These lipid peroxi-
dation products exert cytotoxic effects that could lead to
apoptosis and proximal tubule cell death. There is increased
evidence indicating the involvement of lipid peroxidation
products in various disorders and diseases.31–35 Various
biomarkers for lipid peroxidation have been proposed.20,36
HHE is a reactive by-product derived from lipid peroxidation
of n-3 fatty acids such as eicosapentaenoic and docosa-
hexaenoic acids,20,36 and is one of the most reliable and
sensitive biomarkers of lipid peroxidation. Antibodies against
HHE-modified proteins have been used to detect lipid
peroxidation products in renal I/R injury in rat kidney,21
in pancreatic tissues of rats with spontaneous pancreatitis,37
in light-induced retinal damage in rat retina,38 and in the
biological fluids of patients with asthma and chronic
obstructive pulmonary disease.39 HHE can cause mitochon-
drial dysfunction by enhancing calcium-mediated induction
of the mitochondrial permeability transition and by inhibi-
tion of the mitochondria ATP translocator.40,41 HHE also
was shown to induce apoptosis through inducing apoptotic
Bax coupled with a decrease in anti-apoptotic Bcl-2.42,43 In
addition, HHE can stimulate inducible nitric oxide synthase
in the endothelium through nuclear factor-kB activation,
which can lead to vascular dysfunction by the activation of
various genes that modulate the inflammatory responses.44
Our findings showing increased staining of HHE-related
Figure 11 | Immunohistochemical staining of hydroxy-2-
hexenal (HHE) in the kidney tissue of kidney androgen-
regulated protein 2-peroxisome proliferator-activated
receptor-a (KAP2-PPARa) transgenic mice. (a) Untreated
saline control, (b) 2 days after cisplatin (CP) administration,
(c) testosterone implantation with saline, and (d) testosterone
implantation with CP administration. In CP-treated mice (b), more
than half of the proximal tubules show acute injury with granular
cytoplasmic and cast staining of HHE, whereas the HHE staining is
virtually absent in the kidney tissue of KAP2-PPARa transgenic
mice treated with testosterone and CP (d). Original magnification,
200.
Table 1 |Mitochondria-associated gene expression in line 562 KAP2-PPARa Tg mice
Gene Saline Cisplatin Testosterone+saline Testosterone+cisplatin
Ndufa7 1.000±0.025 0.652±0.023* 1.135±0.045 0.926±0.029
Mt-Nd4l 1.000±0.011 0.681±0.017* 1.054±0.039 0.920±0.054
Cox7b 1.000±0.053 0.685±0.024* 0.976±0.022 0.911±0.022
Atp5b 1.000±0.017 0.667±0.019* 1.046±0.028 0.957±0.040
Atp5J 1.000±0.042 0.661±0.016* 1.056±0.045 0.926±0.043
Polg 1.000±0.022 0.634±0.014* 1.086±0.015 0.906±0.037
Aco2 1.000±0.032 0.683±0.034* 1.095±0.084 1.011±0.044
Mfn1 1.000±0.036 0.607±0.005* 1.115±0.090 1.053±0.035
Mfn2 1.000±0.055 0.569±0.014* 1.024±0.029 0.894±0.045
Values represent mean±s.e. mRNA levels determined by quantitative real-time RT-PCR for at least four mice in each group and normalized to that of control mice (=1.0)
(saline without testosterone).
*Po0.05 compared with control in unpaired Student’s t-test.
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products in the kidney cortex tissue of CP-treated mice and
the absence of HHE-derived lipid peroxidation products
in KAP2-PPARa Tg mice treated with testosterone and
CP suggest that HHE might have a key function in the
pathophysiological process of CP-mediated proximal tubule
cell death. In addition, we find by western blot analysis
that CP- or I/R-induced expression of HHE-modified protein
was also reduced in KAP2-PPARa Tg mice that received
testosterone. Therefore, increased expression of proximal
tubule PPARa reduces the formation and/or scavenging
of HHE, which attenuates or prevents AKI-mediated
oxidative stress, thereby ameliorating the subsequent renal
injury. The fourth mechanism by which increased PPARa
expression ameliorates kidney function in KAP2-PPARa Tg
mice treated with CP or I/R and testosterone is the observed
reduction in necrosis of the S3 segment of the proximal
tubule as shown in Figures 5–7. Although the use of clearance
techniques may better quantify the improvement in renal
function described in our PPARa Tg mice, we believe that
as both serum creatinine and renal histology improve, the
conclusion that the animals were protected seems firmly
established.
Altogether, our study advances our knowledge regarding
the physiological role of PPARa in the kidney and lends
support to the notion that an intact function of proximal
tubule PPARa is important to maintain cell viability during
AKI. Our findings also suggest that proximal tubule PPARa
directly modulates long-chain FAO, regulates mitochondrial
function, and prevents lipid peroxidation, leading to a
significant reduction in acute tubular necrosis of the
proximal tubule during AKI. We believe that in addition
to these proposed mechanisms, additional ones are likely
to account for our observation that increased expression
of PPARa in the proximal tubule results in the prevention of
acute tubular necrosis in the S3 segment of the proximal
tubule in the models of CP and I/R injury to the kidney. For
example, we believe that the observed reduction in PPARa
activity in the kidney tissue of mice with AKI could have
similar effects to the ones seen in PPARa-null mice. In those
mice, the absence of PPARa was shown to be associated
with reduced FAO in the proximal tubule, but also led to
abnormal lysosomal biogenesis and reduced endocytosis of
albumin in the proximal tubule.22,24 In future studies, we
plan to isolate proximal tubules derived from KAP2-PPARa
Tg mice to further define the cellular mechanisms by which
increased expression of proximal tubule PPARa modulates
mitochondrial function and endocytosis, resulting in the
prevention of proximal tubule cell death.
MATERIALS AND METHODS
Transgene construction and generation of Tg mice
Epitope (FLAG)-tagged PPARa under control of the renal proximal
tubule cell-specific and androgen-responsive promoter from the
KAP gene was constructed from pGAL4FLAGPPARa (gift from
Dr Daniel Kelly, Washington University, St Louis, MO, USA) and
pKAP2 (gift from Dr Curt Sigmund, University of Iowa, Iowa City,
IA, USA). pKAP2 contains the KAP promoter driving the expression
of exons 2–5 of the human angiotensin (HAGT) gene (including
introns and 30-UR sequences).44 The 1437-bp BamHI, NotI
fragment of pGAL4 PPARa encoding N-terminal FLAG-tagged
PPARa was ligated into BglII-, NotI-cleaved pKAP2. The resulting
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Figure 12 |Changes in HHE-modified proteins. Western blot
analysis of HHE-modified protein in cisplatin (CP)-treated (a) and
ischemia/reperfusion-treated (b) mouse kidney. Representative
autoradiogram is presented in upper panel. Histogram presents
the relative amount of HHE-modified protein compared with
control (saline) or sham. Bars represent mean±s.e. of three
separate experiments. (a, bottom panel) The relative amounts of
renal HHE in PPARa transgenic mice treated with CP in the
absence of testosterone (*Po0.05 comparing CP with saline-
treated mice). In contrast, in PPARa transgenic mice treated with
testosterone, the amount of renal HHE was significantly reduced
(wPo0.05 when PPARa Tg mice were given testosterone þ CP
compared with PPARa Tg mice that did not receive testosterone
but received CP. (b, bottom panel) The amounts of renal HHE in
wild-type mice treated with testosterone and subjected to either
sham or ischemia–reperfusion injury (I/R-WT) (*Po0.05 comparing
sham-treated mice with I/R-treated mice). In contrast, in PPARa
transgenic mice treated with testosterone, the amount of renal
HHE was reduced when the mice were subjected to
ischemia–reperfusion injury (IR-TG) (wPo0.05 when comparing
PPARa Tg mice that received testosterone and IR injury (I/R-TG)
with wild-type mice that also received testosterone before IR
injury (IR-WT)).
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construct, pKAP2-FLAG-PPARa, contains 1542 bp of the KAP gene
promoter immediately upstream of FLAG-PPARa followed by exons
3–5 and 30-UT sequences of HAGT. The unique AatII and AgeI
sites in pKAP2-FLAG-PPARa were used to liberate an 11,316-bp
fragment containing the KAP promoter, FLAG-PPARa, and all
HAGT sequences from essentially all vector sequences and was gel-
purified using Qiagen gel extraction columns as per manufacturer’s
instructions (Qiagen, Valencia, CA, USA). After ethanol precipita-
tion, the fragment was resuspended in injection buffer to a final
concentration of 2 mg/ml and used to microinject fertilized single-
cell mouse embryos. Pups were screened for the presence of the
KAP2-FLAG-PPARa transgene by PCR using tail DNA as template and
primers corresponding to the KAP promoter (KPTg forward, 50-CC
AACTGTGGAAAACCACCT-30) and PPARa (KPTg reverse, 50-GTG
GGGAGAGAGGACAGATG-30) sequences. Three founder lines
(#560, #561, and #562) were identified from a total of 36 pups
generated. The experiments described in this study were carried out
using mice corresponding to founder line #562.
Mice used for these experiments were 15–20 weeks of age. Wild-
type age- and sex-matched mice were used as controls in the studies
described herein. Only female mice were used for experiments.
There was no difference in baseline weight in a comparison of Tg
with wild-type mice. Mice were housed in a temperature- and light-
controlled environment and provided food and water. To investigate
the effects of PPARa induction, wild-type and KAP2-PPARa Tg
female mice were treated with testosterone by the subcutaneous
administration of a 5-mg testosterone pellet designed for continuous
release for 21 days (Innovative Research of American, Sarasota, FL,
USA). BUN and creatinine were measured by an enzymatic assay as
previously described.8 All experimental procedures were approved
by the Animal Care and Use Committee of the Central Arkansas
Veterans Health Care System (Little Rock, AR, USA) and were in
accordance with the National Institutes of Health and American
Physiological Society’s Guiding Principles in the Care and Use of
Laboratory Animals.
In vivo model of CP-induced AKI
KAP2-PPARa Tg and wild-type mice, 15–20 weeks old, were
assigned to treatment groups. Animals received single intraperito-
neal doses of saline (control) or CP (20 mg per kg body weight).
After treatment, the animals were killed. Blood was collected for
determining BUN and creatinine and testosterone concentration in
serum. Tissues were harvested and frozen in liquid nitrogen for RNA
or protein isolation. For histopathological evaluation, kidneys were
collected in 10% neutral buffered formalin.
In vivo model of I/R-induced AKI
Ischemia was induced in anesthetized (sodium pentobarbital, 50 mg/
kg, i.p.) female mice by exposure of the kidneys under sterile
conditions through a midline incision. The kidneys were decapsu-
lated and both renal hila were clamped with small vascular clamps
for 50 min and released. Sham operations were also performed
in which the kidneys were manipulated as described, without
induction of ischemia. After surgery, the animals were returned to
their cages and allowed free access to food and water. Mice were
killed 24 h after ischemia. Blood was collected for determining BUN
and creatinine and testosterone concentration in serum.
Survival after I/R- or CP-induced AKI
The comparison of survival rate of wild-type and KAP2-PPARa Tg
mice after both groups were treated with testosterone pellet before
AKI was induced was carried out by the Kaplan–Meier method.
Statistical significance was assessed by the log-rank test.
Analysis of gene expression by real-time RT-PCR
Total RNA was extracted with TRIzol Reagent (Invitrogen, Carlsbad,
CA, USA) from both wild-type and Tg mice (line 562) with or with
testosterone pellet after saline or CP intraperitoneal injection. Total
RNA extract was treated with 1 U of RQ1 RNase-free DNase per
microgram of total RNA, at 37 1C for 1 h before RT reaction. RT was
performed at 42 1C for 50 min in a total volume of 20ml containing
1 mg of RNA, 0.5 mg of oligo (dT)12–18, and 200 U of superscript II
RNase H RT. Subsequently, RT was inactivated by incubation at
70 1C for 15 min, followed by treatment with RNase H at 37 1C for
30 min. Real-time PCR was carried out using a DNA Engine
OPTICON 2 continuous fluorescence detector (MJ Research,
Waltham, MA, USA) with SYBR Green I technology. In each
experiment, triplicates of 50 ng cDNA (total RNA equivalent) of
samples were amplified in a 50-ml reaction containing 1 iQ SYBR
Green Supermix (Bio-Rad, Hercules, CA, USA). The real-time PCR
conditions are: 1 cycle at 50 1C for 2 min followed by 1 cycle at 95 1C
(10 min); 40 cycles at 95 1C (15 s), 61 1C (25 s), and 72 1C (16 s).
Specificity of the amplified product was confirmed by melting curve
analysis. For relative quantification, a standard curve was generated
from a six-step cDNA dilution series. Samples were amplified with
primers for PPARa, MCAD, LCAD, VLCAD, L-CPT1, and glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH). The relative expres-
sion of PPARa, MCAD, LCAD, L-CPT1, and GAPDH were
calculated from the standard curve. Relative quantity was calculated
by the ratio of the gene-specific and the appropriate GAPDH
expression. The primer sequences in the real-time RT-PCR were for
PPARa: 50-AAAGAGGCAGAGGTCCGATT-30 (forward), 50-AGCAA
GGTGACTTGGTCGTT-30 (reverse); MCAD: 50-TGCCCTGGATAG
GAAGACAT-30 (forward), 50-AGCGAGTTCAACCTTCATCG-30
(reverse); LCAD: 50-TCTTTTCCTCGGAGCATGAC-30 (forward),
50-TCCAGCTTTCTCCCATTCTG-30 (reverse); VLCAD: 50-AGGTG
GAGGACGACACTTTG-30 (forward), 50-TCTCTGCCAAGCGAGC
ATAC-30 (reverse), L-CPT1: 50-GATGTGGACCTGCATTCCTT-30
(forward), 50-TCCTTGTAATGTGCGAGCTG-30 (reverse); and GAPDH:
50-CACTCTTCCACCTTCGATGC-30 (forward), 50-CCCTGTTGCTGTA
GCCGTAT-30 (reverse). To assess Tg expression in different tissue,
RT-PCR was performed with FLAG-specific primer 50-GGATTAC A
AGGATGACGACGATAAG-30 (forward) and PPARa 50-specific
primer TACACCAGCTTCAGCCGAATAGTTC-3 (reverse).
Assessment of the expression of mitochondria-associated
genes by a mitochondria-specific microarray (MitoChip) and
validation of microarray results by real-time PCR
MitoChip is an oligonucleotide microarray developed at the
National Center for Toxicological Research (NCTR). It consists of
542 genes that are associated with mitochondrial structure and
functions and are encoded by both nuclear and mitochondrial
genomes. The expression level of mitochondria-associated genes in
the kidney of line 562 Tg mice under four conditions (saline, CP,
testosteroneþ saline, and testosteroneþCP) was measured using
MitoChip as described previously.45 Also, the expression level of
significantly altered genes was confirmed using real-time PCR. A set
of genes selected for validation included NADH dehydrogenase
(ubiquinone) 1 a subcomplex 7 (Ndufa7), mitochondrial NADH-
ubiquinone oxidoreductase chain 4l (mt-Nd4l), cytochrome c
oxidase subunit VIIb (Cox7b), ATP synthase Hþ transporting
mitochondrial F1 complex beta subunit (Atp5b), ATP synthase Hþ
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transporting mitochondrial F0 complex subunit F (Atp5j), aconitase 2
(Aco2), mitofusin 1 (Mfn1), and mitofusin 2 (Mfn2). The primer
sequences for the real-time PCR are shown in Table 2.
Statistical analysis of microarray data
The expression level of each gene in a sample was calculated by the
average log2 ratio of the sample fluorescence intensity (Cy5) to
reference intensity (Cy3) from two arrays printed on each slide.
Universal Mouse Reference RNA was used as a reference on each
array during hybridization. Average expression level of housekeeping
genes and Arabidopsis genes on the array was used as a normalizing
covariate. The effects associated with CP, testosterone, and their
interactions were evaluated under a fixed effect linear model.
Analyses were carried out using the GLM procedure of SAS 8.2 (SAS
Institute, SAS/STAT, User’s Guide, Cary, NC, USA). The fold change
in expression of each gene in samples exposed to CP was calculated
by the ratio of the average of least squares means of expression level
in the treatments of CP and CPþ testosterone to the average of least
squares means of expression level in the treatments of saline and
salineþ testosterone. The fold change of CP effect in the presence of
testosterone was calculated by the ratio of the least squares mean of
expression levels of samples treated with CPþ testosterone to the
least squares mean of expression levels of samples treated with
salineþ testosterone, whereas the fold change of CP effect in absence
of testosterone was calculated in the same way using the data from
the samples treated with CP and saline. The interaction is the ratio
of the fold change of CP effect in the presence of testosterone to the
fold change of CP effect in the absence of testosterone. The results
were further classified into different molecular functions or
biological processes (Gene Ontologies) using the database from
the Mouse Genome Informatics web site (http://www.informatics.
jax.org). The overall treatment effect on expression level of a group
of genes was tested using a modified meta-analysis method for
combining P-values.
Immunoprecipitation
Immunoprecipitation was carried out according to manufacturer’s
instructions, using Seize X Protein G Immunoprecipitation Kit
(Pierce, Rockford, IL, USA). PPAR polyclonal antibody (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) was immobilized with Protein
G gel using the cross-linker DSS. Kidney tissue protein extract of
3 mg from the mice either treated with testosterone or no
testosterone was used for the immunoprecipitation. The antigen
bound to antibody-protein G gel was eluted using a primary amine
elution buffer (pH 2.8) as fractions. Each fraction was the separated
on SDS-PAGE and immunoblotting was performed using a dilution
of 1:1000 PPARa monoclonal antibodies (Affinity bioreagents,
Golden, CO, USA).
MCAD activity analysis
MCAD activity assay was performed in kidney tissue extracts
following protocol previously described by Lehman et al.46 with
minor modifications. Kidneys were homogenized in cold 100 mM
HEPES with 0.1 mM EDTA (pH 7.6). The homogenates were then
centrifuged briefly at 4 1C and the MCAD activity was measured
immediately on the supernatant at 37 1C. Two microliters of
supernatant were added to 200 ml of reaction solution of 100 mM
HEPES buffer (pH 7.6), 0.1 mM EDTA, 200mM ferricenium
hexafluorophosphate, 0.5 mM sodium tetrathionate, and 50 mM
octanoyl-CoA. The absorbance decrease at 300 nm in the ferrice-
nium ion was determined by SpectraMax microplate spectro-
photometer (Molecular Devices, Sunnyvale, CA, USA) over the
initial 60-s period. The values were corrected by subtracting the
background absorbance of a tissue blank, measured in the absence of
octanoyl-CoA in the reaction solution. Results are presented as
means±s.e. of MCAD activity relative to that obtained for control
mice, which was set arbitrary as 100% in each experiment and was
calculated from at least four independent experiments.
Immunohistochemistry and histopathology
Immunohistochemical staining was performed on paraffin-
embedded tissue sections from wild-type and PPARa Tg untreated
and CP-treated mice, as well as testosterone-induced untreated and
CP-treated PPARa Tg mice using a monoclonal PPARa antibody
(Affinity Bioreagents, Golden, CO, USA) or monoclonal antibody
against 4-hydroxy-2-hexenal (HHE)-modified protein (NOF Corp,
Tokyo, Japan). The biotinylated anti mouse antibody was visualized
using the ABC Vectastain Kit (Vector Laboratories, Burlingame, CA,
USA). We evaluated histopathological alterations in the kidneys 2
days after the mice were treated with saline or CP, or 24 h after I/R
injury. Kidneys were removed, fixed in 10% neutral buffered
formalin, dehydrated with serial alcohols, and embedded in paraffin.
We stained 3-mm-thick paraffin sections with hematoxylin and
eosin and the periodic acid-Schiff (PAS) method.47 To evaluate
morphological damage to the kidney after CP injection, the follow-
ing parameters were graded on a scale from 0 to 4 as described
previously.48 tubular necrosis, loss of brush border, tubular degene-
ration, cast formation, presence of neutrophils, edema, red blood
cell extravasation, and distal damage.
Western blot analysis
Kidney tissue was homogenized in lysis buffer (50 mM Tris (pH 7.4),
100 mM NaCl, 2.5 mM ethylenediaminetetraacetic acid, 1% Triton X-
100, 0.5% NP-40, 2.5 mM Na3VO4, 1 mM phenylmethylsulfonyl
fluoride, 25 mg/ml aprotinin and leupeptin, and 50 mg/ml Soybean
trypsin inhibitor) and sonicated briefly for 10 s subsequently
centrifuged at 11,000 g for 10 min at 4 1C, and the supernatant
was collected. Supernatants containing 50 mg of protein were
separated on a 12% sodium dodecylsulfate-polyacrylamide gel
electrophoresis and then electroblotted to a nitrocellulose mem-
brane. The membrane was blocked for 1 h with 5% nonfat dried
milk in TBS-T buffer (20 mM Tris, pH 7.6, 100 mM NaCl, 0.1%
Tween 20). Western blot was performed using monoclonal antibody
to HHE (NOF Corporation, Tokyo, Japan) at 1:1000 dilution and
membranes were incubated overnight in TBS-T buffer containing
5% nonfat dried milk at room temperature. After washing three
Table 2 | Real-time PCR primers for analysis of mitochondria-
associated gene expression
Gene Forward primer Reverse primer
Ndufa7 CCCAGTCACAAGCTGTCCAA ACACCAGGGCCTTTTGTGAG
Mt-Nd4l CCACATATGGAGGCATTGCT GGCATGGGACTTAACAGGTG
Cox7b GGTGGAGCCATCTTCTGTGT CAGCTGGCACGACTACTGAT
Atp5b ACCTCGGTGCAGGCTATCTA GGATAGATGCCCAACTCAGC
Atp5j TTCGGTCAGCAGTCTCTGTG GCCTGTCGCTTTGATTTGTA
Polg AAAGGCTCCTTGGAAAAACG AAGCACATCTGAAAGCCTGAG
Aco2 ACCACACCTTCAACGAGACC GTCCAGAGTGGGTCAGGACA
Mfn1 GTCAGCGGTGAAAGCAAAGT AACCCTCTTCTCTGCTGCTG
Mfn2 CTGTGCCAGCAAGTTGACAT TTCCTGAGCAGTTTGGCTCT
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times with TBS-T buffer, the membranes were incubated with a
horseradish peroxidase-conjugated goat anti-rabbit IgG as a second
antibody (1:5000 dilution) for 1 h at room temperature. Proteins
were visualized using by enzyme-linked enhanced chemilumines-
cence (Amersham, Arlington Heights, IL, USA). Signals on the blots
were visualized by autoradiography and quantitated by densitometry
using ImageQuant image analysis system (Molecular Dynamics,
Sunnyvale, CA, USA).
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